Corticosteroid Mediates Acute Respiratory Distress Syndrome

• Status: Recruiting
• Trial end date: 0000-00-00
• Target enrollment: 20
• Participant gender: Both

Summary

It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response. The aim of this study was to determine IL-18 levels in serum of patients with acute respiratory distress syndrome and to investigate whether corticosteroid attenuate its levels.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate
• Last Updated: 2016-06-29

Criteria

Inclusion Criteria:

1. Able to provide written informed consent;

2. Aged 18-85 years;

3. Confirmed diagnosis of ARDS by Berlin criterion: the ratio of the partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) less than 200 mmHg and persistent bilateral infiltrates on chest computed tomography

Exclusion Criteria:

1. Active tuberculosis and disseminated fungal infection;

2. Chronic corticosteroid application

3. Patients with organ dysfunction, such as severe liver dysfunction, adrenal insufficiency, severe cardiopulmonary dysfunction;

4. Hypogammaglobulinemia or other autoimmune disease;

5. Acquired immunodeficiency syndrome;

6. Refuse to use corticosteroid;

7. Pregnant or nursing